Studying Biomarkers in Patients With Pancreatic Cancer
|ClinicalTrials.gov Identifier: NCT00900003|
Recruitment Status : Completed
First Posted : May 12, 2009
Last Update Posted : December 12, 2013
RATIONALE: Studying samples of tissue in the laboratory from patients with cancer may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.
PURPOSE: This research study is studying biomarkers in patients with pancreatic cancer.
|Condition or disease||Intervention/treatment|
|Pancreatic Cancer||Genetic: protein analysis Other: laboratory biomarker analysis|
- To determine whether the cellular localization of BRCA1 can predict how patients with pancreatic cancer will respond to cytotoxic agents (e.g., fluorouracil or gemcitabine hydrochloride) or radiotherapy.
- To identify pre-treatment markers that can be used to correlate with clinical outcomes of survival and recurrence.
- To determine if a method of extracting and identifying secreted cytokines and growth factors from biopsy tissue can now be applied to the pancreatic cancer population.
OUTLINE: Tissue samples from biopsies performed during pancreatectomy are collected from the Vanderbilt Ingram Cancer Center Human Tissue Acquisition Core for laboratory biomarker studies. Proteins secreted by cancer cells and/or cancer-associated cells are studied by extracting and identifying secreted cytokines and growth factors from biopsy tissue. The integrity of the DNA repair pathway in pancreatic cancer is analyzed by Rad51 and phosphorylated DNA-PK foci formation. Markers are correlated with clinical outcome.
Patients are followed for recurrence, relapse, and death from disease.
|Study Type :||Observational|
|Actual Enrollment :||53 participants|
|Official Title:||Developing Biomarkers in Pancreatic Cancer|
|Study Start Date :||May 2007|
|Primary Completion Date :||March 2013|
|Study Completion Date :||March 2013|
pancreatic cancer patients
pancreatic cancer patients with excess tissue collected at the time of standard of care surgery
Genetic: protein analysis
Using material that is already being acquired as a component of clinical care (only that which is excess after routine clinical care), we will determine if pre-treatment markers can be used to correlate with clinical outcomes of survival and recurrence. Examples of such markers include studying if the integrity of DNA repair pathway in pancreatic cancers, analyzed by Rad51 and phosphorylated DNA-PK foci formation, correlates with tumor response to radiotherapy, chemotherapy, and overall survival. The markers targeted are proteins secreted by cancer cells and/or cancer associated cells.Other: laboratory biomarker analysis
A method of extracting and identifying secreted cytokines and growth factors from tissues of the quantity of typical biopsy tissues has been developed.The purpose of this study is to determine if this method of biomarker discovery can now be applied to pancreatic cancer population.
- Cellular localization of BRCA1 as a predictor of response to cytotoxic agents or radiotherapy [ Time Frame: following collection of all pancreatic tissue specimens and patient outcome data ]Examine the location of BRCA1 in the cells and determine if this location predicts patient response to the chemotherapy drugs given
- Correlation of pre-treatment markers with survival and recurrence [ Time Frame: at expiration date of final patient enrolled ]Compare and contract of biomarkers in patient's tissue that are detected before treatment has a relationship to their survival and recurrence of their cancer
- Application of a method of extracting and identifying secreted cytokines and growth factors from biopsy tissue to the pancreatic cancer population [ Time Frame: upon collection of pancreatic tissue for each patient ]Researchers will determine if the methods they have developed for extracting and identifying cytokines in biopsy tissue can be applied to the pancreatic cancer tissue
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00900003
|United States, Tennessee|
|Vanderbilt-Ingram Cancer Center - Cool Springs|
|Nashville, Tennessee, United States, 37064|
|Vanderbilt-Ingram Cancer Center at Franklin|
|Nashville, Tennessee, United States, 37064|
|Vanderbilt-Ingram Cancer Center|
|Nashville, Tennessee, United States, 37232-6838|
|Study Chair:||A. Bapsi Chakravarthy, MD||Vanderbilt-Ingram Cancer Center|